PURPOSE: To examine the acute cardiotoxicity of internal mammary chain (IMC) irradiation with concurrent trastuzumab. MATERIALS AND METHODS: Clinical and cardiac function data were collected on 59 patients with early breast cancer who were treated with adjuvant trastuzumab and chemotherapy with or without radiotherapy (often including IMC) at BC Cancer Agency in 2005. RESULTS: Forty-four of fifty-nine patients received adjuvant radiotherapy (RT). Thirteen had left-sided IMC RT. For left-sided RT, IMC inclusion increased the mean percentage dose to 5% of the heart, but the mean doses to 50% and 90% of the heart were similar. Median baseline left ventricular ejection fraction (LVEF) was 62% and similar in all groups. Median absolute decrease in LVEF after RT was 4%, which was not significantly different according to side or inclusion of IMCs. Trastuzumab was stopped in 11 of 59 patients (18.6%) due to decrease in LVEF. After median follow up of 15 months, three patients developed clinical congestive heart failure, none of whom received left-sided IMC RT. CONCLUSIONS: There was no excess acute cardiotoxicity observed with the combination of left-sided IMC irradiation and concurrent trastuzumab.
PURPOSE: To examine the acute cardiotoxicity of internal mammary chain (IMC) irradiation with concurrent trastuzumab. MATERIALS AND METHODS: Clinical and cardiac function data were collected on 59 patients with early breast cancer who were treated with adjuvant trastuzumab and chemotherapy with or without radiotherapy (often including IMC) at BC Cancer Agency in 2005. RESULTS: Forty-four of fifty-nine patients received adjuvant radiotherapy (RT). Thirteen had left-sided IMC RT. For left-sided RT, IMC inclusion increased the mean percentage dose to 5% of the heart, but the mean doses to 50% and 90% of the heart were similar. Median baseline left ventricular ejection fraction (LVEF) was 62% and similar in all groups. Median absolute decrease in LVEF after RT was 4%, which was not significantly different according to side or inclusion of IMCs. Trastuzumab was stopped in 11 of 59 patients (18.6%) due to decrease in LVEF. After median follow up of 15 months, three patients developed clinical congestive heart failure, none of whom received left-sided IMC RT. CONCLUSIONS: There was no excess acute cardiotoxicity observed with the combination of left-sided IMC irradiation and concurrent trastuzumab.
Authors: Pelagia G Tsoutsou; Yazid Belkacemi; Joseph Gligorov; Abraham Kuten; Hamouda Boussen; Nuran Bese; Michael I Koukourakis Journal: Oncologist Date: 2010-11-01
Authors: Mousumi M Andersen; Diandra Ayala-Peacock; Jessie Bowers; Banks W Kooken; Ralph B D'Agostino; Jennifer H Jordan; Sujethra Vasu; Alexandra Thomas; Heidi D Klepin; Doris R Brown; W Gregory Hundley Journal: Am J Cardiol Date: 2020-04-02 Impact factor: 2.778
Authors: G A Tanteles; J Whitworth; J Mills; I Peat; A Osman; G P McCann; S Chan; J G Barwell; C J Talbot; R P Symonds Journal: Br J Cancer Date: 2009-07-14 Impact factor: 7.640